Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - Drug metabolism - Bacterial synthetic community

ABSTRACT: Bacterial culture with drugs acquired on Q Exactive with chromatographic separation on a Phenomenex polar C18 column (Kinetex 2.6 um, 150 x 2.1 mm). Reversed-phase, ESI positive.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Bacteria (ncbitaxon:2)

SUBMITTER: Pieter C. Dorrestein

PROVIDER: MSV000095331 | GNPS | Sun Jul 14 16:47:00 BST 2024

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Similar Datasets

Drug metabolism - Bacterial synthetic community

Project description:Bacterial culture with drugs acquired on Q Exactive with chromatographic separation on a Phenomenex polar C18 column (Kinetex 2.6 um, 150 x 2.1 mm). Reversed-phase, ESI positive.

2024-07-14 | MSV000095331 | MassIVE

20231123_ChemProp2_Non-targeted Metabolomics of Xenobiotic Biotransformations using synthetic gut bacterial community

Project description:ChemProp2 Dataset: Investigating potential biotransformations with a panel of 45 Drugs on Synthetic Community (Com20) to elucidate Drug-Microbiome-Host Dynamics

2023-12-05 | MSV000093571 | MassIVE

185-member bacterial synthetic community

Project description:A single bacterial genus maintains root development in a complex microbiome

| PRJNA543313 | ENA

Transcriptional Responses of M. tuberculosis to inhibitors of metabolism

Project description:Transcriptional profiling of M.tuberculosis was performed using 430 whole-genome microarrays to measure the effects of 75 different drugs, drug combinations or different growth conditions at various times relative to a sample of logarithmically growing MTb. Analysis of this data set revealed 150 underlying clusters of coordinately regulated genes as described in Boshoff et al., 2004. Keywords = Gene clusters Keywords = Mechanism of action Keywords = tuberculosis Keywords = antimycobacterial drugs Keywords = natural product Keywords = respiration

2004-09-01 | E-GEOD-1642 | biostudies-arrayexpress

Transcriptional Responses of M. tuberculosis to inhibitors of metabolism

2004-09-01 | GSE1642 | GEO

GNPS - 20231123_ChemProp2_Non-targeted Metabolomics of Xenobiotic Biotransformations using synthetic gut bacterial community

Project description:ChemProp2 Dataset: Investigating potential biotransformations with a panel of 45 Drugs on Synthetic Community (Com20) to elucidate Drug-Microbiome-Host Dynamics

2023-12-05 | MSV000093571 | GNPS

Ecological drivers of bacterial community assembly in synthetic phycospheres.

Project description:In the nutrient-rich region surrounding marine phytoplankton cells, heterotrophic bacterioplankton transform a major fraction of recently fixed carbon through the uptake and catabolism of phytoplankton metabolites. We sought to understand the rules by which marine bacterial communities assemble in these nutrient-enhanced phycospheres, specifically addressing the role of host resources in driving community coalescence. Synthetic systems with varying combinations of known exometabolites of marine phytoplankton were inoculated with seawater bacterial assemblages, and communities were transferred daily to mimic the average duration of natural phycospheres. We found that bacterial community assembly was predictable from linear combinations of the taxa maintained on each individual metabolite in the mixture, weighted for the growth each supported. Deviations from this simple additive resource model were observed but also attributed to resource-based factors via enhanced bacterial growth when host metabolites were available concurrently. The ability of photosynthetic hosts to shape bacterial associates through excreted metabolites represents a mechanism by which microbiomes with beneficial effects on host growth could be recruited. In the surface ocean, resource-based assembly of host-associated communities may underpin the evolution and maintenance of microbial interactions and determine the fate of a substantial portion of Earth's primary production.

| S-EPMC7035482 | biostudies-literature

Defined spatial structure stabilizes a synthetic multispecies bacterial community.

Project description:This paper shows that for microbial communities, "fences make good neighbors." Communities of soil microorganisms perform critical functions: controlling climate, enhancing crop production, and remediation of environmental contamination. Microbial communities in the oral cavity and the gut are of high biomedical interest. Understanding and harnessing the function of these communities is difficult: artificial microbial communities in the laboratory become unstable because of "winner-takes-all" competition among species. We constructed a community of three different species of wild-type soil bacteria with syntrophic interactions using a microfluidic device to control spatial structure and chemical communication. We found that defined microscale spatial structure is both necessary and sufficient for the stable coexistence of interacting bacterial species in the synthetic community. A mathematical model describes how spatial structure can balance the competition and positive interactions within the community, even when the rates of production and consumption of nutrients by species are mismatched, by exploiting nonlinearities of these processes. These findings provide experimental and modeling evidence for a class of communities that require microscale spatial structure for stability, and these results predict that controlling spatial structure may enable harnessing the function of natural and synthetic multispecies communities in the laboratory.

| S-EPMC2587551 | biostudies-literature

Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model

Project description:we assessed characteristic molecular and proteomic signatures in rat liver treated with drugs (pyrazinamide, ranitidine, enalapril, carbamazepine, and chlorpromazine) that are known to cause DILI in humans. In the present study, we assessed the characteristic gene expression signature for DILI in a rat model. Rats were administered representative drugs that are already known to induce DILI in humans and transcriptomic changes in rat liver were analyzed. The representative drugs, which induce three types (hepatocellular, mixed, and cholestatic) of DILI, that were used in this study were pyrazinamide (PZA, 150~1500 mg/kg), ranitidine (RAN, 209.5~2095 mg/kg), enalapril (ENA, 148.65~1486.5 mg/kg), carbamazepine (CBZ, 97.85~978.5 mg/kg), and chlorpromazine (CPZ, 7.1~71 mg/kg).

2013-08-16 | E-GEOD-49631 | biostudies-arrayexpress

Deciphering Differential Gut Bacterial Drug Metabolism with Activity-Based Protein Profiling

Project description:Gut bacterial β-glucuronidases (GUS) promote the toxic side effects of therapeutics by reactivating drugs from their inactive glucuronide conjugates. It is increasingly clear that the interindividual variability of bacterial GUS-producing species in the gut microbiota contributes to differential drug responses. Indeed, the anticancer drug irinotecan exhibits variable clinical toxicity outcomes that have been linked to interindividual differences in the composition of the gut microbiota. However, identification of the specific GUS enzymes responsible for drug metabolism in the context of the complexity of the human fecal microbiota has not been achieved. Here we pinpoint the specific bacterial GUS enzymes that reactivate SN-38, the active metabolite of irinotecan, from complex human fecal microbiota samples with activity-based protein profiling (ABPP). We identify and quantify gut bacterial GUS enzymes from human feces with ABPP-enabled proteomics and then integrate this information with ex vivo kinetics to reveal the specific GUS enzymes responsible for the reactivation of SN-38. The same ABPP approach also reveals the molecular basis for differential gut bacterial GUS inhibition between human fecal samples. Taken together, this work provides an unprecedented pipeline to identify the specific bacterial GUS enzymes responsible for drug-induced GI toxicity from the complexity of human feces, which may serve as highly precise biomarkers of clinical outcomes for irinotecan and other therapeutics.

2019-12-03 | PXD014864 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data